VERAXA Biotech to go public via a SPAC merger with Voyager Acquisition in a $1.64bn deal.

VERAXA Biotech, an advancing a premier drug discovery and development engine for ADCs and other novel antibody-based therapy concepts, agreed to go public via a SPAC merger with Voyager Acquisition, a special-purpose acquisition company, in a $1.64bn deal. “VERAXA is committed to developing and delivering the next wave of safe and highly efficacious cancer therapies. Our platform technologies can be applied to empower multiple therapeutic strategies spanning next-generation antibody-drug conjugates including our BiTAC ADCs and bi-specific BiTAC immune cell engagers. Side effects too often limit today’s cancer therapies and prevent doctors from applying optimal dose levels. Our latest platform innovation, the BiTAC format, is designed to specifically address this issue and create first-in-class drug candidates with unprecedented safety and efficacy," Christoph Antz, VERAXA CEO and Co-Founder.